ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Proteostasis Therapeutics, Inc." (PTI) Report Updated: Feb 20, 2017 | Print This Page

Get more stock ratings by Louis Navellier

"Proteostasis Therapeutics, Inc." (PTI)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: CLCD,ARRY,CRBP,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
February March April May June July August September October November December January

Rating: Weekly View

This Week: B down upgrade
Last Week: C same upgrade
Two Weeks Ago: N up no change
service keys

"Proteostasis Therapeutics, Inc."© quotemedia

Company Profile